Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma

Historically, administration of dacarbazine to sarcoma patients was limited by frequent treat-ment-related nausea/vomiting and neutropenia. These toxicities are now largely preventable with contemporary antiemetics and growth factor support. In this single-arm, phase II study, dacarbazine 850 mg/m(2...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Tine, Brian A, Weiss, Mia C, Hirbe, Angela C, Oppelt, Peter J, Abaricia, Sarah, Trinkaus, Kathryn, Luo, Jingqin, Berry, Shellie, Ruff, Tyler, Callahan, Cheryl, Toensikoetter, Jacqui, Ley, Jessica, Siegel, Marilyn J, Dehdashti, Farrokh, Siegel, Barry A, Adkins, Douglas R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504645/
https://www.ncbi.nlm.nih.gov/pubmed/34646430
http://dx.doi.org/10.1177/20363613211052498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504645/
https://www.ncbi.nlm.nih.gov/pubmed/34646430
http://dx.doi.org/10.1177/20363613211052498

Ejemplares similares